SCHEMBL10205122

SCHEMBL10205122

CC1(C)C(=O)Nc2cccc(CNc3nc(Nc4ccc(C5CCN(C(=O)CN)CC5)cc4)ncc3Cl)c21

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ STK17A Q9UEE5 1/20 0.46
▸ STAT6 P42226 2/20 0.46
▸ FLT4 P35916 2/20 0.45
▸ KDR P35968 2/20 0.45
▸ AXL P30530 1/20 0.45
▸ NTRK1 P04629 6/20 0.43
▸ SYK P43405 1/20 0.43
▸ TNK2 Q07912 1/20 0.42
▸ NTRK3 Q16288 1/20 0.42
▸ NTRK2 Q16620 1/20 0.42
▸ JAK3 P52333 2/20 0.41
▸ WEE1 P30291 1/20 0.41
▸ PTK2 Q05397 2/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ JAK1 P23458 1/20 0.40
▸ TTK P33981 1/20 0.40
▸ EGFR P00533 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10206601 0.93 AXL (0.44) STK17ASTAT6FLT4KDRAXL
SCHEMBL14331659 0.93 NTRK1 (0.44) STK17ASTAT6FLT4KDRAXL
SCHEMBL10206600 0.90 FLT4 (0.44) STK17ASTAT6FLT4KDRAXL
SCHEMBL10207048 0.89 FLT4 (0.44) STK17ASTAT6FLT4KDRAXL
SCHEMBL10206599 0.89 AXL (0.42) STK17ASTAT6FLT4KDRAXL
SCHEMBL10206602 0.88 TNK2 (0.43) STK17ASTAT6FLT4KDRAXL
SCHEMBL14331651 0.88 AXL (0.40) STK17ASTAT6FLT4KDRAXL
SCHEMBL10206633 0.87 EGFR (0.46) STK17ASTAT6FLT4KDRAXL
SCHEMBL10205126 0.87 NTRK1 (0.40) STK17ASTAT6FLT4KDRAXL
SCHEMBL10206621 0.87 JAK3 (0.43) STK17ASTAT6FLT4KDRAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655358-B1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2014-11-19 — — EP disclosed
US-8546443-B2 Benzylic oxindole pyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 — — US disclosed
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-27 — — US disclosed
WO-2012085126-A1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES MKI67, CCNI, CCNB1 STK17A 3446/4885STAT6 1155/4885FLT4 2572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback